



Market data	
EPIC/TKR	AVCT
Price (p)	32.0
12m High (p)	98.0
12m Low (p)	32.0
Shares (m)	69.0
Mkt Cap (£m)	22.1
EV (£m)	13.8
Free Float*	59%
Market	AIM

\*As defined by AIM Rule 26

**Description**

Avacta is a pre-clinical stage biotechnology company developing biotherapeutics based on its proprietary Affimer protein technology. It benefits from near-term revenues from research and diagnostic reagents.

**Company information**

CEO Alastair Smith  
 CFO Tony Gardiner  
 Chairman Trevor Nicholls

+44 1904 217 070  
[www.avacta.com](http://www.avacta.com)

**Key shareholders**

Directors	6.1%
IP Group	24.8%
Lombard Odier	10.8%
Aviva	9.6%
Ruffer LLP	7.1%
JO Hambro	6.7%

**Diary**

1H'18	Sloan Kettering feasibility
Oct-18	Finals
Jan-19	AGM

**Analysts**

Martin Hall 020 7148 1433  
[mh@hardmanandco.com](mailto:mh@hardmanandco.com)  
 Dorothea Hill 020 7148 1433  
[dmh@hardmanandco.com](mailto:dmh@hardmanandco.com)  
 Gregoire Pave 020 7148 1434  
[gp@hardmanandco.com](mailto:gp@hardmanandco.com)

## Avacta Group

### Commendable rate of progress

Avacta (AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the drug industry, despite its limitations. The significant technical and commercial benefits of Affimers is being recognised though increased corporate interest, on-going evaluations, and deal flow. Meanwhile, AVCT has made stunning progress in its strategic goal to enter first-in-man trials in 2020, which now looks likely to be with a valuable bi-specific Affimer immuno-oncology asset.

- ▶ **Strategy:** AVCT is aiming to commercialise its Affimer technology through bespoke research tools, collaborative deals and by identifying and developing its own proprietary therapeutic leads. AVCT has sufficient cash resources to identify an Affimer lead to be ready for first-in-man trials in 2019.
- ▶ **Interims:** Sales increased 16% to £1.47m (£1.26m), driven by a 50% rise in Life Sciences (custom service and reagent Affimers). Investment in personnel and US business development infrastructure generated an underlying EBIT loss a little ahead of forecasts at -£4.28m (-£3.71m). Net cash was £0.5m better at £8.3m.
- ▶ **2015 objectives:** In 2015, AVCT set out a number of objectives to advance the potential use of Affimer technology in both therapeutics and diagnostics. In just two years, the company has made incredible progress and looks set to enter the clinic with a potentially valuable and novel bi-specific Affimer asset in 2020.
- ▶ **Risks:** Affimers represent a new disruptive technology and the potential customer base might take time to recognise their advantages. While all new drug development carries a high risk, Avacta has hit a number of important milestones over the last two years which have reduced the risk profile.
- ▶ **Investment summary:** AVCT has made considerable progress towards its goal of having its own proprietary Affimer-based drugs and growing a profitable reagents business. By itself, the company has identified potential leads and completed both *in vitro* and *in vivo* pharmacokinetic pre-clinical, efficacy and immunogenicity tests. Awareness of the potential of Affimers is also being enhanced through the rising number of collaborative deals being signed.

**Financial summary and valuation**

Year-end July (£m)	2014	2015	2016	2017E	2018E	2019E
Sales	1.81	2.17	2.74	3.15	3.60	5.49
R&D spend	-0.03	-1.50	-2.60	-3.40	-4.50	-5.50
EBITDA	-2.28	-4.79	-6.66	-8.13	-9.40	-9.25
Underlying EBIT	-2.85	-5.39	-7.60	-9.20	-10.47	-10.32
Reported EBIT	-5.51	-5.66	-7.98	-9.62	-10.94	-10.83
Underlying PBT	-2.83	-5.29	-7.51	-9.15	-10.48	-10.37
Statutory PBT	-5.48	-5.57	-7.89	-9.58	-10.94	-10.89
Underlying EPS (p)	-4.38	-6.46	-8.75	-11.74	-13.07	-12.55
Statutory EPS (p)	-9.72	-6.86	-9.31	-12.36	-13.74	-13.30
Net (debt)/cash	7.33	19.52	13.17	4.31	-6.22	-16.29
Capital increases	0.02	21.05	0.01	0.06	0.00	0.00
EV/sales (x)	17.7	14.8	11.7	10.2	8.9	5.8

Source: Hardman & Co Life Sciences Research

## Interim results

### Key features

#### Operational

- ▶ **Identification of clinical lead:** Although considerable progress has been made in progressing its PD-L1 programme, a second immuno-oncology programme (lymphocyte activation gene 3 protein (LAG3)) has made enormous strides, such that a bi-specific Affimer is the likely lead into the clinic.
- ▶ **Affimer XT platform:** This family of Affimers binds to human serum albumin with varying affinity, providing half-life in serum of up to two weeks. These have been designed to extend the serum half-life of Affimer therapeutics but can also be licensed for use as a linker to carry small protein/peptide cytotoxic payloads.
- ▶ **Moderna:** The research partnership with Moderna Therapeutics investigating Affimer targeting of messenger RNA is due to complete in May 2018, which could lead to Moderna exercising an option to develop one of the Affimers in the pipeline, or to an extension of the research programme.
- ▶ **Partnerships:** The flexibility of Affimers is clearly being recognised with an increased number of partnerships, including Glythera, FIT Biotech and OncoSec.

#### Financial

- ▶ **Sales:** Underlying sales grew 16% to £1.47m (£1.26m), with all the growth coming from the Life Sciences division. 58% (54%) of sales are now derived outside the UK.
- ▶ **R&D:** Investment in R&D rose 16% to -£1.48m (-£1.28m), as forecast, given increased spend on its own proprietary therapeutic programme, which is being charged directly to the P&L account.
- ▶ **Administration:** SG&A costs increased 15% to -£3.81m (-£3.32m), reflecting the greater investment in personnel and the opening of US business development offices on both the east (Philadelphia) and west (San Diego) coasts.
- ▶ **Underlying EBIT:** Increased sales were offset by the higher than expected SG&A spend, such that the underlying EBIT loss was ca.£0.25m higher than expected.
- ▶ **Net cash/(debt):** Overall cash burn was ca.£0.5m below expectations, such that the net cash position at the end of the reporting period was £8.3m, in contrast to our forecast of £7.3m.

#### Avacta interims – actual vs. forecasts

Half-year analysis £m	1H'17 actual	1H'18 actual	Growth %	1H'18 forecast	Delta Δ
Life Sciences	0.46	0.69	50.4%	0.55	+0.14
Animal Health	0.80	0.77	-3.5%	0.80	-0.03
<b>Group sales</b>	<b>1.26</b>	<b>1.47</b>	<b>16.2%</b>	<b>1.35</b>	<b>+0.12</b>
COGS	-0.38	-0.46	20.2%	-0.45	-0.01
R&D	-1.28	-1.48	15.7%	-1.50	+0.02
SG&A	-3.06	-3.81	14.8%	-3.45	-0.36
<b>Underlying EBIT</b>	<b>-3.71</b>	<b>-4.28</b>	<b>+15.2%</b>	<b>-4.05</b>	<b>-0.23</b>
<b>Net cash/(debt)</b>	<b>16.1</b>	<b>8.3</b>		<b>7.8</b>	<b>+0.5</b>

*Figures may not add up exactly due to rounding  
Source: Hardman & Co Life Sciences Research*

## Affimer development update

In 2015, management set a number of goals to develop the concept of Affimers as therapeutic and diagnostic agents in order to realise the commercial potential. The aim was to prove that the theoretical technical advantages of Affimers could be translated into products with commercial benefits. In just two years, the company has made progress at a commendable rate with both its therapeutic and diagnostic programmes, through both in-house development and partnerships. AVCT remains very much on target to move into clinical development with at least one in-house therapeutic programme during 2020.

### Avacta objectives set in 2015

	Objective	Progress
1.	Develop the first in-house Affimer therapeutic candidate for clinical development	✓
2.	Build a pipeline of therapeutic Affimers and enabling Affimer platform technologies for licensing or future in-house development	✓
3.	Secure further partnership deals to develop the Affimer platform for both therapeutics and diagnostics	✓
4.	Grow a custom Affimer revenue stream with the potential for long term royalties	✓

*Source: Avacta, Hardman & Co Life Sciences Research*

## Affimer therapeutics

Following discussion with its scientific advisory board, management took the decision not to try and identify new drug targets, but to develop Affimers that could resolve problems associated with known and well-validated targets. The aim was to lower the risk and to minimise the time needed to identify a lead candidate to take into human trials. Consequently, the company focused on two areas, immuno-oncology (IO) and haematology.

### Immuno-oncology

Throughout the development of in-house therapeutic Affimers, PD-L1 has been the main target and to date, in excess of 50 PD-L1 antagonists have been generated and characterised with the best having single and double digit nanomolar binding affinities. These Affimers have been generated with high lab-scale yield and have been shown to possess significant tumour growth reduction in animal models, similar to the PD-L1 antibody control.

However, at the company's capital markets day (7<sup>th</sup> February 2018), AVCT indicated that it had also made significant progress in developing Affimers for another surface receptor known to inhibit T-cell function, namely LAG3<sup>1</sup>. In its interim statement, management stated that progress has been sufficiently rapid and encouraging with its Affimer LAG3 antagonist Affimer, that it has decided to take a more ambitious approach to its clinical development options.

The company decided originally to focus on PD-L1, as a well understood and validated IO target, in order to get clinical data for the Affimer platform as quickly as possible. However, from a commercial perspective, a potential issue with PD-L1 inhibitors is that there are many such putative drugs in clinical development and that


<sup>1</sup> Nguyen, LT and Ohashi, PS. Clinical blockade of PD1 and LAG3 — potential mechanisms of action. *Nature Reviews Immunology*, 2015, 15, 45-56.

it is a crowded market place. In addition, the clinical effectiveness of approved PD-L1 inhibitors has not been as great as expected when used in a broader population of patients. This is largely believed to be due to an effect called ‘T-cell exhaustion’, which can be reduced by blocking the interaction of LAG3.

Therefore, combining the two Affimer targets into a single bi-specific Affimer would take AVCT into a much less competitive field and be a more valuable asset. Of course, all the potentially competitive products are based on bi-specific antibodies, which will be very large molecules, and more difficult and expensive to make. Management believes that it will still be ready to have this bi-specific Affimer ready for first-in-man trials in 2020.

Although there remains a considerable amount of work to be done in readiness for a Phase I clinical trial, management has set out a clear schedule to achieve this goal.

**Bi-specific pathway to clinic**




Source: Avacta

**Affimer XT**

In parallel, AVCT has been working to develop Affimers that bind to human serum albumin (HAS) to extend the serum half-life of Affimer drugs from hours to days or weeks. This technology can be applied to any other third party, small therapeutic payload, creating the possibility for licensing deals independent of other Affimer drugs.

**Affimer XT – mechanism of action**



Source: Avacta


Given that peptide drugs have a short half-life in serum, which requires them to be administered regularly, AVCT sees clear potential to use Affimers as a 'linker' mechanism that will be recirculated along with the HSA, thereby extending the half-life of the payload. This could result in a significantly improved dosing regimen from daily to weekly or fortnightly.

## Affimer reagents

Although most of the focus is on the Affimer therapeutics opportunity, AVCT continues to progress the potential use of Affimers as diagnostics reagents. Initially, products were generated for use as research tools, allowing scientists to provide independent external validation of Affimers and increase awareness via publications in peer-reviewed journals. However, this business has also developed considerably over the last two years.

Avacta has focused its business development and production activities on providing a custom service to generate Affimer reagents on demand, with a view to getting these into third parties' future products, and generating royalty payments. It currently has work-in-progress for over 40 projects. Earlier work on such projects has led to over 25 evaluations being undertaken by external customers. One of the more advanced has led to AVCT granting the first product development license to a top-three global diagnostics company in 1H'18. Given the level evaluation activity being undertaken, management expects more license deals to be signed in 2018 and beyond.

### Ongoing Affimer evaluations (>25)



Source: Avacta

One of the first customers to publicly talk about its experience of Affimers is Covance, part of Lab Corp, one of the world's largest CROs. Avacta has been working closely with Covance to develop reagent Affimers that resolve a critical step in the manufacture of antibodies, called "anti-idiotypic" binders. Development of anti-idiotypic antibodies can be a long and potentially difficult process, which can result in delays to therapeutic programmes. AVCT has helped to resolve this issue with an elegant, reliable, and fast solution that has been adopted by Covance. With thousands on new monoclonal antibodies in development around the world, and each one benefiting potentially from an anti-idiotypic reagent, this has the potential to become a solid high margin business in coming years. For 2018, Hardman & Co is forecasting reagent revenues of around £1.5m.

## Financial forecasts

### Profit & Loss

- ▶ **Sales:** Although 1H'18 sales were modestly better than expected, the difficulty in predicting timing of sales, coupled with the increased level of activity outside the UK, has led us to tweak our full-year sales down £0.1m to £3.1m.
- ▶ **R&D spend:** The reported R&D number refers only to the spend on therapeutic Affimers *plus* the amortisation charge. Capitalised R&D on the reagents business is not included in this figure and can be found in the cashflow statement.
- ▶ **SG&A:** Increased US infrastructure with offices on both the east and west coast, coupled with the employment on additional headcount has led us to increase full-year SG&A by £0.5m to ca.£8.0m.

Profit & Loss account						
Year-end July (£m)	2015	2016	2017	2018E	2018E	2020E
Life Sciences	0.44	0.70	1.15	1.55	1.90	3.69
Animal Health	1.37	1.46	1.59	1.60	1.70	1.80
<b>Sales</b>	<b>1.81</b>	<b>2.17</b>	<b>2.74</b>	<b>3.15</b>	<b>3.60</b>	<b>5.49</b>
COGS	-0.53	-0.90	-0.94	-0.97	-1.07	-1.25
<b>Gross profit</b>	<b>1.29</b>	<b>1.27</b>	<b>1.79</b>	<b>2.18</b>	<b>2.53</b>	<b>4.25</b>
<b>Gross margin</b>	<b>71%</b>	<b>59%</b>	<b>66%</b>	<b>69%</b>	<b>70%</b>	<b>77%</b>
SG&A	-4.11	-5.16	-6.79	-7.98	-8.50	-9.06
R&D	-0.03	-1.50	-2.60	-3.40	-4.50	-5.50
EBITDA	-2.28	-4.79	-6.66	-8.13	-9.40	-9.25
Depreciation	-0.52	-0.60	-0.93	-1.07	-1.07	-1.07
Amortisation	-0.06	-0.64	-0.65	-0.80	-0.95	-1.00
Licensing/royalties	0.00	0.00	0.00	0.00	0.00	0.00
<b>Underlying EBIT</b>	<b>-2.85</b>	<b>-5.39</b>	<b>-7.60</b>	<b>-9.20</b>	<b>-10.47</b>	<b>-10.32</b>
Share-based costs	-0.25	-0.27	-0.39	-0.42	-0.47	-0.51
Exceptional items	-2.41	0.00	0.00	0.00	0.00	0.00
Statutory EBIT	-5.51	-5.66	-7.98	-9.62	-10.94	-10.83
Net financials	0.03	0.10	0.09	0.04	0.00	-0.06
<b>U/L Pre-tax profit</b>	<b>-2.83</b>	<b>-5.29</b>	<b>-7.51</b>	<b>-9.15</b>	<b>-10.48</b>	<b>-10.37</b>
Reported pre-tax	-5.48	-5.57	-7.89	-9.58	-10.94	-10.89
Tax payable/credit	0.65	0.92	1.53	1.09	1.46	1.69
Tax rate	-12%	-16%	-19%	-11%	-13%	-16%
<b>Underlying net income</b>	<b>-2.18</b>	<b>-4.38</b>	<b>-5.98</b>	<b>-8.07</b>	<b>-9.02</b>	<b>-8.68</b>
Statutory net income	-4.84	-4.65	-6.37	-8.49	-9.49	-9.19
<b>Ordinary 10p shares:</b>						
Period-end (m)	49.80	68.38	68.39	68.98	69.08	69.18
Weighted average (m)	49.73	67.71	68.39	68.69	69.03	69.13
Fully diluted (m)	42.85	51.91	70.39	73.21	73.50	73.85
<b>Underlying Basic EPS (p)</b>	<b>-4.38</b>	<b>-6.46</b>	<b>-8.75</b>	<b>-11.74</b>	<b>-13.07</b>	<b>-12.55</b>
Statutory Basic EPS (p)	-9.72	-6.86	-9.31	-12.36	-13.74	-13.30
<b>U/I Fully-diluted EPS (p)</b>	<b>-4.20</b>	<b>-6.22</b>	<b>-8.17</b>	<b>-10.97</b>	<b>-12.22</b>	<b>-11.74</b>
Stat. Fully-diluted EPS (p)	-9.31	-6.60	-8.70	-11.55	-12.85	-12.43
<b>DPS (p)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>

Source: Hardman & Co Life Sciences Research

## Balance sheet

- ▶ **Net cash:** Avacta had £8.3m of cash on its balance sheet at 31<sup>st</sup> January 2017, and no debt. This was about £0.5m higher than forecast.
- ▶ **Tax credit:** The tax credit in relation to R&D spend on the balance sheet at the end of January was £1.7m, of which £1.2m is likely to be received during 2H'18.
- ▶ **Cash balance:** Based on current forecasts, and in the absence of any up-fronts associated with licensing deals, our forecasts suggest that Avacta will have a capital increase before reporting fully-year 2018 numbers in order to have sufficient working capital to get auditor sign-off.

Balance sheet						
@31 <sup>st</sup> July (£m)	2015	2016	2017	2018E	2019E	2020E
Shareholders' funds	19.13	35.86	29.89	21.40	11.91	2.72
Cumulated goodwill	0.00	0.00	0.00	0.00	0.00	0.00
Total equity	19.13	35.86	29.89	21.40	11.91	2.72
Share capital	5.06	6.92	6.92	6.92	6.92	6.92
Reserves	14.08	28.94	22.97	14.48	4.99	-4.20
Provisions/liabilities	0.86	0.34	0.34	0.34	0.34	0.34
Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
Long-term loans	0.00	0.00	0.00	0.00	0.00	0.00
Short-term loans	0.00	0.00	0.00	0.00	0.00	0.00
less: Cash	7.33	9.52	9.17	4.31	-6.22	-16.29
less: Deposits	0.00	10.00	4.00	0.00	0.00	0.00
<b>Invested capital</b>	<b>12.67</b>	<b>16.68</b>	<b>17.06</b>	<b>17.42</b>	<b>18.47</b>	<b>19.35</b>
Fixed assets	1.55	3.74	3.45	3.18	3.05	3.06
Intangible assets	10.36	11.48	12.30	14.10	16.01	17.70
Inventories	0.33	0.27	0.16	0.18	0.21	0.32
Trade debtors	0.21	0.16	0.25	0.25	0.25	0.25
Other debtors	0.55	0.97	1.03	1.04	1.19	1.81
Tax liability/credit	1.07	1.42	1.20	1.09	1.46	1.69
Trade creditors	-0.66	-0.40	-0.65	-0.85	-1.15	-1.55
Other creditors	-0.74	-0.95	-0.68	-1.57	-2.54	-3.93
Debtors less creditors	0.43	1.19	1.15	-0.04	-0.79	-1.73
<b>Invested capital</b>	<b>12.67</b>	<b>16.68</b>	<b>17.06</b>	<b>17.42</b>	<b>18.47</b>	<b>19.35</b>
<b>Net cash/(debt)</b>	<b>7.33</b>	<b>19.52</b>	<b>13.17</b>	<b>4.31</b>	<b>-6.22</b>	<b>-16.29</b>

Source: Hardman & Co Life Sciences Research

## Cashflow

- ▶ **1H'18 cashflow:** Operating cashflow was about £0.5m better than forecast, largely because of higher non-cash items – depreciation and amortisation.
- ▶ **Cap-ex:** Investment in cap-ex has reverted to normalised levels in fiscal 2018, with -£0.43m being spent in 1H'18.
- ▶ **Tax received:** No R&D-related tax refund was received from HMRC in 1H'18, although forecasts assume that £1.2m will be received before the fiscal year end.
- ▶ **Cash balance:** Forecasts suggest that Avacta will have ca.£4.3m cash at 31<sup>st</sup> July. As the company continues to deliver on its clearly-stated objectives, we believe that the company will have an equity issue prior to the announcement of full year results and in the absence of any significant up-fronts from licensing deals.

Cashflow						
Year-end July (£m)	2015	2016	2017	2018E	2019E	2020E
Trading profit	-2.85	-5.39	-7.60	-9.20	-10.47	-10.32
Depreciation	0.52	0.60	0.93	1.07	1.07	1.07
Amortisation	0.06	0.64	0.65	0.80	0.95	1.00
<i>Inventories</i>	-0.21	0.07	0.11	-0.02	-0.03	-0.11
<i>Receivables</i>	0.20	-0.36	-0.13	0.00	0.00	0.00
<i>Payables</i>	0.06	-0.08	-0.06	-0.20	-0.30	-0.40
Change in working capital	0.04	-0.38	-0.07	-0.22	-0.33	-0.51
Exceptionals/provisions	0.00	-0.44	0.00	0.00	0.00	0.00
Other	-0.29	0.00	0.00	0.00	0.00	0.00
<b>Company op cashflow</b>	<b>-2.55</b>	<b>-4.90</b>	<b>-6.07</b>	<b>-7.55</b>	<b>-8.78</b>	<b>-8.75</b>
Net interest	0.03	0.10	0.09	0.03	0.00	0.00
Tax paid/received	0.01	0.57	1.75	1.20	1.09	1.46
Operational cashflow	<b>-2.52</b>	<b>-4.23</b>	<b>-4.24</b>	<b>-6.32</b>	<b>-7.69</b>	<b>-7.30</b>
Capital expenditure	-0.81	-2.86	-0.66	-0.80	-0.94	-1.09
Capitalised R&D	-3.06	-1.76	-1.47	-1.80	-1.91	-1.69
Sale of fixed assets	0.00	0.00	0.00	0.00	0.00	0.00
<b>Free cashflow</b>	<b>-6.38</b>	<b>-8.86</b>	<b>-6.37</b>	<b>-8.92</b>	<b>-10.53</b>	<b>-10.07</b>
Dividends	0.00	0.00	0.00	0.00	0.00	0.00
Acquisitions	0.00	0.00	0.00	0.00	0.00	0.00
Disposals	2.21	0.00	0.00	0.00	0.00	0.00
<b>Cashflow after invests.</b>	<b>-4.17</b>	<b>-8.86</b>	<b>-6.37</b>	<b>-8.92</b>	<b>-10.53</b>	<b>-10.07</b>
Share repurchases	0.00	0.00	0.00	0.00	0.00	0.00
Share issues	0.02	21.05	0.01	0.06	0.00	0.00
Cash/(debt) acquired	0.00	0.00	0.00	0.00	0.00	0.00
<b>Change in net debt</b>	<b>-4.15</b>	<b>12.19</b>	<b>-6.36</b>	<b>-8.85</b>	<b>-10.53</b>	<b>-10.07</b>
Hardman FCF/share (p)	-5.1	-6.3	-6.2	-9.2	-11.1	-10.6
Opening net cash	11.48	7.33	19.52	13.17	4.31	-6.22
<b>Closing net cash</b>	<b>7.33</b>	<b>19.52</b>	<b>13.17</b>	<b>4.31</b>	<b>-6.22</b>	<b>-16.29</b>

Source: Hardman & Co Life Sciences Research

## Company matters

### Registration

Incorporated in the UK with company registration number: 04748597

### Registered Office

Unit 20, Ash Way  
Thorp Arch Estate  
Wetherby  
LS23 7FA

+44 1904 217 070

[www.avacta.com](http://www.avacta.com)

### Board of Directors

Board of Directors			
Position	Name	Remuneration	Audit
Chairman	Trevor Nicholls	C	M
Chief Executive Officer	Alastair Smith		
Chief Financial Officer	Tony Gardiner		
Non-executive director	Alan Aubrey	M	C
Non-executive director	Mike Owen	M	

*M = member; C = chair*


*Source: Company reports*

The Nominations committee is convened on an 'as required' basis and chaired by the Chairman.

### Share capital

At the date of this report, there were 68,989,487 Ordinary shares of 10p in issue. In addition, there are 4.8m share options outstanding.

### Shareholders



*Source: Hardman and Co Life Sciences Research*

## Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, because of possible human or mechanical error by Hardman & Co, its affiliates or its sources, Hardman & Co cannot guarantee the accuracy, validity, timeliness or completeness of any information provided for in this report. No guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, unless in case of gross negligence, fraud or wilful misconduct. Hardman & Co expressly disclaims any warranties of merchantability or fitness for a particular purpose. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co have been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fee, commission or other remuneration in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legal/research-disclosures>

Hardman & Co has a personal dealing policy which debars staff and consultants from dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. They may be allowed to hold such securities if they were owned prior to joining Hardman & Co or if they were held before the company or legal entity appointed Hardman & Co. In such cases, sales will only be allowed in limited circumstances, generally in the two weeks following publication of figures. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or funds covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for its own account or for other parties and neither does it undertake investment business. We may provide investment banking services to corporate clients.

Hardman & Co does not make recommendations. Accordingly, we do not publish records of our past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities/companies and legal entities but has no scheduled commitment and may cease to follow these securities/companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors or geographical areas. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make their own independent decisions and obtain their own independent advice regarding any information, projects, securities, or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information this constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly, its distribution in the United Kingdom is restricted. Neither Hardman & Co nor any other person authorised by the Financial Conduct Authority (United Kingdom) (FCA) has approved or authorised the contents of this document for the purposes of section 21 FSMA. Accordingly, this document is only directed at:

- i. persons who have professional experience in matters relating to investments falling within Article 19(5) (Investment Professionals) or Article 49 (High Net Worth Companies, Unincorporated Associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) (the Order);
- ii. certified high net worth individuals within the meaning of Article 48 of the Order;
- iii. certified sophisticated investors and self-certified sophisticated investors within the meaning of Article 50 and Article 50A of the Order;
- iv. associations of high net worth investors or sophisticated investors within the meaning of Articles 51 of the Order; and
- v. any other person whom it may lawfully be communicated.

(together, the relevant persons).

This document is directed at only relevant persons and must not, under any circumstances be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is only available to relevant persons and will be engaged in only with relevant persons. The UK compensation scheme and rules for the protection of private customers do not apply to the services provided or products sold by non-UK regulated affiliates.

The receipt of this document by any person is not to be taken as constituting the giving of investment advice by Hardman & Co to any to any such person.

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co.

By accepting this document, the recipient agrees to be bound by the limitations set out in this notice.

*This notice shall be governed and construed in accordance with English law.*

*Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority (FCA) under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.*

*Hardman & Co Research Limited (trading as Hardman & Co)  
35 New Broad Street  
London  
EC2M 1NH*

*+44 (0) 20 7194 7622  
Follow us on Twitter @HardmanandCo*

*(Disclaimer Version 4 – Effective from April 2018)*

## Status of Hardman & Co's research under MiFID II

*Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies and legal entities about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.*

*In particular, Article 12(3) of the Directive states: 'The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'*

*The fact that we are commissioned to write the research is disclosed in the disclaimer, and the research is widely available.*

*The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>*

*In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.*

## Hardman & Co team

### Management team

+44 (0)20 7194 7622

John Holmes	jh@hardmanandco.com	+44 (0)20 7194 7629	Chairman
Keith Hiscock	kh@hardmanandco.com	+44 (0)20 7194 7630	CEO
David Banks	db@hardmanandco.com	+44 (0)20 7194.7622	Corporate Advisory/Finance

### Business development and investor engagement

+44 (0)20 7194 7622

Richard Angus	ra@hardmanandco.com	+44 (0)20 7194 7635
Max Davey	md@hardmanandco.com	+44 (0)20 7194 7622
Antony Gifford	ag@hardmanandco.com	+44 (0)20 7194 7622
Ann Hall	ah@hardmanandco.com	+44 (0)20 7194 7622
Gavin Laidlaw	gl@hardmanandco.com	+44 (0)20 7194 7627
Vilma Pabilionyte	vp@hardmanandco.com	+44 (0)20 7194 7637

### Analysts

+44 (0)20 7194 7622

#### Agriculture

Doug Hawkins	dh@hardmanandco.com
Yingheng Chen	yc@hardmanandco.com

#### Bonds / Financials

Brian Moretta	bm@hardmanandco.com
Mark Thomas	mt@hardmanandco.com

#### Building & Construction

Tony Williams	tw@hardmanandco.com
Mike Foster	mf@hardmanandco.com

#### Consumer & Leisure

Steve Clapham	sc@hardmanandco.com
Mike Foster	mf@hardmanandco.com
Jason Streets	js@hardmanandco.com

#### Life Sciences

Martin Hall	mh@hardmanandco.com
Dorothea Hill	dmh@hardmanandco.com
Grégoire Pavé	gp@hardmanandco.com

#### Media

Derek Terrington	dt@hardmanandco.com
------------------	---------------------

#### Mining

Paul Mylchreest	pm@hardmanandco.com
-----------------	---------------------

#### Oil & Gas

Angus McPhail	if@hardmanandco.com
---------------	---------------------

#### Property

Mike Foster	mf@hardmanandco.com
-------------	---------------------

#### Services

Mike Foster	mf@hardmanandco.com
-------------	---------------------

#### Special Situations

Steve Clapham	Brian Moretta
Paul Singer	Chris Magennis
Yingheng Chen	yc@hardmanandco.com

#### Tax Enhanced Services

Brian Moretta	bm@hardmanandco.com
---------------	---------------------

#### Technology

Milan Radia	mr@hardmanandco.com
-------------	---------------------

#### Utilities

Nigel Hawkins	nh@hardmanandco.com
---------------	---------------------

### Hardman & Co

35 New Broad Street  
London  
EC2M 1NH

Tel: +44(0)20 7194 7622

[www.hardmanandco.com](http://www.hardmanandco.com)

